Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-controlled randomized safety and tolerability study of inhaled liposomal amikacin (Arikace) in bronchiectasis with chronic Pseudomonas aeruginosa infection
2007-007940-92Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of amikacin liposome inhalation suspension in bronchiectasis and Pseudomonal infection (3 arms), sponsored by Insmed Incorporated. Primary endpoint: Treatment-emergent adverse events. Started Mar 2008; status: completed.
02
Drugs
amikacin liposome inhalation suspension
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2007-007940-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007940-92.